# Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Study · id `cardio:ct-nct05573477` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05573477](<https://clinicaltrials.gov/study/NCT05573477>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05573477

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 255 participants.

## Technical summary

Registry record NCT05573477. Randomized; double masking; primary purpose treatment. Start 2022-11-16 (actual); primary completion 2025-08-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 255 participants (enrolled count; ClinicalTrials.gov record NCT05573477, source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)
- Started: 2022-11-16 (actual) (ClinicalTrials.gov record NCT05573477, source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)
- Primary completion: 2025-08-31 (actual) (ClinicalTrials.gov record NCT05573477, source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)
- Completion: 2026-02-28 (actual) (ClinicalTrials.gov record NCT05573477, source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05573477, source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05573477-2026-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
- Condition: Essential Hypertension
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): ATB-1011
- Intervention (Drug): ATB-1012
- Intervention (Drug): ATB-1013
- Intervention (Drug): ATB-1011 placebo
- Intervention (Drug): ATB-1012 placebo
- Intervention (Drug): ATB-1013 placebo
- Lead sponsor: Autotelicbio
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: babc69fbe7a51e1ee2bcf7f0fea46ea90a27f5c1b69bf8fbe89cfd5696fed590
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
